<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on 카지노 바카라 products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
-
2022 년 3 월 7 일카지노 바카라 of Organizational Restructuring and Personnel Appointments at Our Subsidiaries
125.51 KB
-
2021 년 12 월 24 일Notification of Partial Changes in Marketing Approval for the Indication of GnRH Antagonist RELUMINA® Tablets (Relgorix) for Endometriosis
149.23 KB
-
2021 년 12 월 16 일Notice Regarding the Publication on a Phase 3 카지노 바카라mparative Study for GnRH Antagonist RELUMINA® Tablets (Relugolix) for Endometriosis
121.81 KB
-
2021 년 11 월 1 일RaQualia Pharma and 카지노 바카라 Pharmaceutical Sign Joint Research Agreement
253.67 KB
-
2021 년 10 월 19 일Toray and 카지노 바카라 Conclude Business Collaboration Agreement for Adhesion Barrier
387.71 KB
-
2021 년 9 월 27 일Licensing Agreement on Relugolix 카지노 바카라mbination Tablet in Women's Health Indications
225.72 KB
이전 뉴스 카지노 바카라의 경우 Aska Pharmaceutical Holdings Co., Ltd. 웹 사이트를 참조하십시오.